Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Patient Access Advocacy for BTK Inhibitors

The Inflation Reduction Act: Implications for Patient Access in CL

Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

Decision-Making in CLL: The Role of Real-World Evidence

Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Optimizing Therapy Sequencing in CLL

Empowering Patients: Key Considerations for BTK Inhibitor Adherence

Switching From Ibrutinib to Zanubrutinib Improves Cardiac Safety and Workflow: Mohit Narang, MD

Switching Patients With CLL From Ibrutinib for Zanubrutinib: Mohit Narang, MD

Navigating Value, Efficacy in Modern CLL Treatment: Pierluigi Porcu, MD

Advancing Hematologic Care and the Future of Shared Decision-Making

Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients

Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences

Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making

Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024

Exploring the Efficacy and Safety of Ibrutinib and Venetoclax in CLL

Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi